Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Squamous Cell Carcinoma of Head and Neck 17Head and Neck Neoplasms 10Melanoma 9Carcinoma, Non-Small-Cell Lung 8Neoplasms 6Neoplasm Metastasis 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Stomach Neoplasms 4Ovarian Neoplasms 4Mouth Neoplasms 4Colorectal Neoplasms 4Carcinoma, Merkel Cell 4Carcinoma, Hepatocellular 4Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Laryngeal Neoplasms 3Colonic Neoplasms 3Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Sarcoma 2Recurrence 2Prostatic Neoplasms 2Kidney Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma 2

Interventions

Cisplatin 35Radiotherapy 21Magnetic Resonance Spectroscopy 19Cetuximab 17Specimen Handling 15pembrolizumab 13Carboplatin 13Radiotherapy, Intensity-Modulated 12Fluorouracil 12Docetaxel 121,2-diaminocyclohexaneplatinum II citrate 10Radiation 9Platinum 9Surgical Procedures, Operative 8Paclitaxel 8Drug Therapy 7Biopsy 7Taxes 5Surveys and Questionnaires 5toripalimab 4X-Rays 4Standard of Care 4Fluorodeoxyglucose F18 4Celecoxib 4(225)Ac-DOTA-c(RGDyK) 4cemiplimab 3Nutritional Status 3Laser Therapy 3Interviews as Topic 3Immunohistochemistry 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Laryngeal Neoplasms × cemiplimab × Head & Neck × Clear all
NCT06980038 2026-06-01

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

NCT07195734 2026-05-19

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
180 enrolled
Head & Neck

Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04862650 2026-02-10

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Ohio State University Comprehensive Cancer Center

Phase 2 Active not recruiting
46 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡